LON:VRP Verona Pharma plc (VRP.L) (VRP) Share Price, News & Analysis Add Share Share Stock Analysis Stock Analysis About Verona Pharma plc (VRP.L) (LON:VRP) Get VRP alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume70,791 shsAverage Volume150,610 shsMarket Capitalization£228 millionAssets Under ManagementN/ADividend YieldN/ANet Expense Ratio0.00%Aggregate RatingN/A ETF Overview Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom. Read More Receive VRP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verona Pharma plc (VRP.L) and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRP ETF News HeadlinesMerck dives into COPD treatments with $10 billion purchase of Verona PharmaApril 19, 2026 | marketwatch.comVerona Pharma plc (VRNA): Jim Cramer Approves The Merck AcquisitionJuly 12, 2025 | msn.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.October 15 at 1:00 AM | The Oxford Club (Ad)Merck Agrees to Buy Verona Pharma for About $10 BillionJuly 9, 2025 | msn.comWolfe Research Initiates Coverage of Verona Pharma plc - Depositary Receipt () (VRNA) with Outperform RecommendationJuly 2, 2025 | msn.comVerona Pharma (VRNA) Achieved Strong Launch for Ensifentrine After FDA ApprovalJune 23, 2025 | msn.comSee More Headlines VRP ETF - Frequently Asked Questions How were Verona Pharma plc (VRP.L)'s earnings last quarter? Verona Pharma plc (VRP.L) (LON:VRP) issued its earnings results on Thursday, February, 27th. The company reported ($30.30) earnings per share for the quarter, topping the consensus estimate of ($30.80) by $0.50. What other stocks do shareholders of Verona Pharma plc (VRP.L) own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verona Pharma plc (VRP.L) investors own include Laura Ashley (ALY), Amerisur Resources (AMER), Alliance Pharma (APH), Akebia Therapeutics (AKBA), AngioDynamics (ANGO), AbbVie (ABBV) and Agree Realty (ADC). 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (LON:VRP) was last updated on 10/29/2020 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verona Pharma plc (VRP.L) Please log in to your account or sign up in order to add this asset to your watchlist. Share Verona Pharma plc (VRP.L) With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
